https://scholars.lib.ntu.edu.tw/handle/123456789/551048
標題: | Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer | 作者: | TUNG-HUNG SU TAI-CHUNG TSENG CHUN-JEN LIU Chou S.-W CHEN-HUA LIU HUNG-CHIH YANG PEI-JER CHEN DING-SHINN CHEN CHI-LING CHEN JIA-HORNG KAO |
公開日期: | 2020 | 出版社: | Wiley-Liss Inc. | 卷: | 147 | 期: | 3 | 起(迄)頁: | 901-908 | 來源出版物: | International Journal of Cancer | 摘要: | To identify the risk factors of oral cancer, we investigated the association between chronic hepatitis C (CHC) and oral cancer, and the development of oral cancer after anti-hepatitis C virus (HCV) therapy. We conducted a nationwide, population-based cohort study from 2004 to 2012 from the Taiwan National Health Insurance Research Database. CHC patients without anti-HCV therapy were matched with those non-HCV patients by age, sex and comorbidities. Moreover, CHC patients who underwent pegylated interferon and ribavirin (PegIFN/RBV) anti-HCV therapy were matched with CHC patients without anti-HCV therapy. A total of 100,058 patients were included in the HCV cohort and non-HCV cohorts, respectively. Their mean age was 59 years and 50% of these were male. CHC infection significantly increased the cumulative incidence of lichen planus and oral cancer. After adjustment for confounders and competing mortality, CHC infection significantly increased the risk of oral cancer (hazard ratio [HR]: 1.677, 95% confidence interval [CI]: 1.392–2.020, p < 0.001). Another 23,735 CHC patients without anti-HCV therapy were matched with 23,735 CHC patients in the treatment cohort. After adjustment for confounders and competing for mortality, the risk of oral cancer was significantly reduced in CHC patients receiving anti-HCV therapy (HR: 0.652, 95% CI: 0.479–0.887, p = 0.007). To minimize the inclusion of pre-existing unidentified oral cancer, we excluded oral cancer developed within the first year of CHC or anti-HCV therapy and found these associations remained statistically significant. In conclusion, CHC significantly increases the risk of oral cancer. Moreover, PegIFN/RBV antiviral therapy significantly reduces the risk of HCV-related oral cancer. ? 2019 UICC |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078586776&doi=10.1002%2fijc.32840&partnerID=40&md5=4d79980008e7f18c74bd81172e5f9f33 https://scholars.lib.ntu.edu.tw/handle/123456789/551048 |
ISSN: | 0020-7136 | DOI: | 10.1002/ijc.32840 | SDG/關鍵字: | peginterferon; ribavirin; antivirus agent; interferon; ribavirin; adult; antiviral therapy; Article; cancer prevention; cancer risk; chronic hepatitis C; cohort analysis; confidence interval; confounding variable; disease association; female; human; incidence; lichen planus; major clinical study; male; middle aged; mortality; mouth cancer; population research; priority journal; risk assessment; risk factor; risk reduction; Taiwan; trend study; aged; case control study; chronic hepatitis C; combination drug therapy; mouth tumor; Adult; Aged; Antiviral Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mouth Neoplasms; Ribavirin; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。